Abstract:
SARS-COV2 has had a devastating impact worldwide, with almost 46 million infections and over 1.2 million death. New Zealand has so far managed to contain the virus's spread with a relatively low number of disease and fatality rate. Even so, developing a meaningful therapeutic intervention for our population is an urgent unmet need. While the research community worldwide is developing a safe and effective vaccine, we have focussed on repurposing FDA approved drugs for other indications to tackle SARS-COV2. This talk will cover drug repurposing of various classes of drugs and the current status of such medications for the treatment of SARS-COV2.